why choose us

First received: November 30, 2022

Clinical Trial: A Bioequivalence Study of Dasatinib Tablet

Study Status: Completed

Recruit Status: Completed

Condition: Leukemia, Myelogenous, Chronic

Study Type: Interventional


Official Title: A Bioequivalence Study Between the Generic Dasatinib Tablet and Reference Product in Vivo

Brief Summary: This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Sprycel® produced by Bristol Myers Squibb after single dose in healthy subjects, so as to provide reference for clinical evaluation and clinical medication; to observe the safety of the dasatinib tablet and the reference drug Sprycel® in healthy subjects under fasting and fed states.

Read more